製品番号: HY-50101

Mavorixafor

(別名: AMD-070; AMD-11070)

8 Cited Publications

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.66%
CAS 番号: 558447-26-0
分子式: C₂₁H₂₇N₅
分子量:349.47

保管条件:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Mavorixafor 構造式

CAS 番号: 558447-26-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (8)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

¹²⁵I-SDF-CXCR4

13 nM (IC₅₀)

HIV-1 (NL4.3 strain)

1 nM (IC₅₀, in MT-4 cells)

HIV-1 (NL4.3 strain)

9 nM (IC₅₀, in PBMCs)

HIV-1 (NL4.3 strain)

3 nM (IC90, in MT-4 cells)

HIV-1 (NL4.3 strain)

26 nM (IC90, in PBMCs)

CXCR アイソフォーム固有の製品をすべて表示 :

HIV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HOS	CC₅₀	>10 μM Compound: 1, AMD-070	Cytotoxicity against human HOS cells Cytotoxicity against human HOS cells	[PMID: 19640718]
HOS	IC₅₀	0.01 μM Compound: 1, AMD-070	Antiviral activity against HIV1 3B infected in human HOS cells Antiviral activity against HIV1 3B infected in human HOS cells	[PMID: 19640718]
HOS	IC₅₀	10 nM Compound: AMD-070	Antiviral activity against HIV1 3B infected in human HOS cells expressing human CXCR4/CCR5/CD4/pHIV-LTR luciferase assessed as inhibition of viral infection to cells Antiviral activity against HIV1 3B infected in human HOS cells expressing human CXCR4/CCR5/CD4/pHIV-LTR luciferase assessed as inhibition of viral infection to cells	[PMID: 20443225]
MT4	IC₅₀	0.003 μM Compound: 2, AMD-070	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells expressing CD4 and CXCR4 assessed as inhibition of virus-induced cytopathicity Antiviral activity against HIV1 NL4.3 infected in human MT4 cells expressing CD4 and CXCR4 assessed as inhibition of virus-induced cytopathicity	[PMID: 20297846]
MT4	IC₅₀	0.016 μM Compound: 2, AMD-070	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity in presence of 10% human serum Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity in presence of 10% human serum	[PMID: 20297846]
MT4	IC₅₀	2.3 ng/mL Compound: AMD-070	Antiviral activity against HIV1 NL4.3 in human MT4 cells Antiviral activity against HIV1 NL4.3 in human MT4 cells	[PMID: 17452489]
MT4	IC₅₀	4.8 nM Compound: 1, AMD070	Antiviral activity against X4 tropic HIV1 NL4.3 infected in CD4 and CXCR4 expressing human MT4 cells assessed as inhibition of viral cytopathicity Antiviral activity against X4 tropic HIV1 NL4.3 infected in CD4 and CXCR4 expressing human MT4 cells assessed as inhibition of viral cytopathicity	[PMID: 21295470]

体外実験

Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)^[1]. Mavorixafor (AMD-070) (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 558447-26-0
性状 Solid
分子量 349.47
分子式 C₂₁H₂₇N₅
Color White to gray
SMILES

NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@@H]3C4=C(CCC3)C=CC=N4
別名

AMD-070; AMD-11070
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (8)

All

Sort by:

Journal Impact Factor

Proc Natl Acad Sci U S A

Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists. [Abstract]

2025 Mar 18;122(11):e2425795122. PMID: 40063796
Cell Mol Life Sci

Crosstalk between purinergic receptor P2Y11 and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages. [Abstract]

2024 Mar 13;81(1):132. PMID: 38472446
Am J Physiol Cell Physiol

Mechanistic insights into SENP1 and OCT4 interaction in promoting drug resistance and stem cell features in colon cancer. [Abstract]

2025 Apr 1;328(4):C1260-C1278. PMID: 40063360
Biosci Rep

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs. [Abstract]

2023 Dec 22;43(12):BSR20230981. PMID: 38131305
Oncol Rep

Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. [Abstract]

2022 Apr;47(4):68. PMID: 35119076
Br J Haematol

CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance. [Abstract]

2023 May;201(3):459-469. PMID: 36535585
PLoS One

Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. [Abstract]

2016 Mar 21;11(3):e0151765. PMID: 26998906
Patent

US20220273751A1.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (286.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8615 mL

14.3074 mL

28.6148 mL

5 mM

0.5723 mL

2.8615 mL

5.7230 mL

10 mM

0.2861 mL

1.4307 mL

2.8615 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

Cells are seeded on a 96-well plate at 5 × 10³ cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 µM AMD3100 or 6.6 µM AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 10⁶). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of Mavorixafor (AMD-070) (2 mg/kg)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88. [Content Brief]

[2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8615 mL	14.3074 mL	28.6148 mL	71.5369 mL
	5 mM	0.5723 mL	2.8615 mL	5.7230 mL	14.3074 mL
	10 mM	0.2861 mL	1.4307 mL	2.8615 mL	7.1537 mL
	15 mM	0.1908 mL	0.9538 mL	1.9077 mL	4.7691 mL
	20 mM	0.1431 mL	0.7154 mL	1.4307 mL	3.5768 mL
	25 mM	0.1145 mL	0.5723 mL	1.1446 mL	2.8615 mL
	30 mM	0.0954 mL	0.4769 mL	0.9538 mL	2.3846 mL
	40 mM	0.0715 mL	0.3577 mL	0.7154 mL	1.7884 mL
	50 mM	0.0572 mL	0.2861 mL	0.5723 mL	1.4307 mL
	60 mM	0.0477 mL	0.2385 mL	0.4769 mL	1.1923 mL
	80 mM	0.0358 mL	0.1788 mL	0.3577 mL	0.8942 mL
	100 mM	0.0286 mL	0.1431 mL	0.2861 mL	0.7154 mL

Keywords

Mavorixafor

8 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Mavorixafor

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Chemokine Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Mavorixafor

CXCR アイソフォーム固有の製品をすべて表示

HIV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Mavorixafor 関連分類

HY-50101 関連分類